[Cancer Management and Research] A retrospective review sought to determine the effect of postoperative radiotherapy on patients with stage IIIA(N2) non-small cell lung cancer with EGFR mutation.
[Breast Cancer: Targets and Therapy] In this report, the researchers review the treatment of triple-negative breast cancer and specifically shed light on advances in immunotherapy and newly approved drugs for this challenging-to-manage disease.
[OncoTargets and Therapy] In this review, researchers summarize use, indications, and clinical safety and efficacy of olaparib, a PARP inhibitor, in the treatment of ovarian cancer, including in patients with BRCA mutations.
[Blood and Lymphatic Cancer: Targets and Therapy] First approved in 2011, the CD30 directed antibody-drug conjugate brentuximab vedotin is used in previously untreated and R/R classical Hodgkin lymphoma (cHL). In this review, researchers discuss the expanded indications for BV in cHL to include maintenance therapy after ASCT and in combination with chemotherapy and immunotherapy.
[OncoTargets and Therapy] Researchers outline the case of a 93-year-old female with advanced ATC who received initial treatment with apatinib.
[Lung Cancer: Targets and Therapy] Data from two phase 2 studies, NP28673 and NP28761, suggest that patients with previously treated ALK-positive NSCLC experienced rapid time to systemic response and time to CNS response with alectinib.
[Breast Cancer: Targets and Therapy] This study compared the technique, process, and outcomes of external beam radiation therapy with those of 3-dimensional conformal radiation therapy, finding that benefits of the APBI technique included fewer side effects and reduced treatment periods.
[Journal of Hepatocellular Carcinoma] In this study, investigators sought to determine how socioeconomic differences influenced outcomes for patients in Florida with HCC. They found that despite having lower socioeconomic status, Hispanic patients with HCC fared better than both black and white patients with HCC.
[OncoTargets and Therapy] In this review, researchers describe the pathophysiology of myeloma bone disease and discuss the significance of preventing skeletal-related events in patients with MM.
[OncoTargets and Therapy] The aim of this study was to evaluate the impact of SNM on nutritional status, treatment-related toxicity, QoL, response rates, and survival in LA-NPC patients treated by RT.
